The $409,000 contract will see Proteomics International test a novel drug for degenerative and inflammatory diseases on behalf of the Australian arm of pharmaceutical company Sironax Ltd. The study is part of a Phase I clinical trial examining the safety, tolerability and pharmacokinetics of the drug, and will be undertaken over the next 12 months.
Pharmacokinetics is the study of what happens to drugs once they are inside the body, including the rate at which they are absorbed, distributed, metabolised and excreted.
Proteomics International managing director Dr Richard Lipscombe said the contract with Linear was one of Proteomics International’s largest to date. “With Australia as a leading destination for clinical trials, we are seeing strong demand for our specialist testing services in this fast-growing space,” he said.